biostudies-literatureUnknown47(1)Li ZJinling HospitalThe KDIGO 2021 guidelines suggest that individuals who test positive for serum anti-phospholipase A2 receptor (anti-PLA2R) antibodies may not require a renal biopsy to establish a diagnosis of membranous nephropathy (MN). However, it is imperative to acknowledge that MN can coexist with other chronic kidney diseases. In instances where MN is comorbid with IgA nephropathy, diabetic nephropathy, or focal segmental glomerulosclerosis, the therapeutic approach tends to be analogous. Nevertheless, there is a significant disparity in both the treatment regimen and the prognosis between MN and renal amyloidosis, with variations existing even among distinct subtypes of renal amyloidosis. Given that both MN and renal amyloidosis exhibit a predilection for the geriatric population, it is prudent to Renal failure2486562https://www.ebi.ac.uk/biostudies/studies/S-EPMC12016244biostudies-literatureMembranous nephropathy concurrent with renal amyloidosis: a six-patient report and literature review.PMC12016244Liu JLi ZZuo KHuang XZhang MXu FJiao CZhu SCheng ZfalseMembranous nephropathy concurrent with renal amyloidosis: a six-patient report and literature review.The KDIGO 2021 guidelines suggest that individuals who test positive for serum anti-phospholipase A2 receptor (anti-PLA2R) antibodies may not require a renal biopsy to establish a diagnosis of membranous nephropathy (MN). However, it is imperative to acknowledge that MN can coexist with other chronic kidney diseases. In instances where MN is comorbid with IgA nephropathy, diabetic nephropathy, or focal segmental glomerulosclerosis, the therapeutic approach tends to be analogous. Nevertheless, there is a significant disparity in both the treatment regimen and the prognosis between MN and renal amyloidosis, with variations existing even among distinct subtypes of renal amyloidosis. Given that both MN and renal amyloidosis exhibit a predilection for the geriatric population, it is prudent to 2025-01-01T00:00:00Z2025 Dec2025-07-02T03:04:59.582Z2025-07-02T03:04:59.582ZS-EPMC120162444026052310.1080/0886022X.2025.2486562